Matthew K Fust insider trades
Open-market stock purchases and sales by Matthew K Fust, Director at Crinetics Pharmaceuticals, Inc, from SEC Form 4 filings since Jan 6, 2010.
Track record: 0% of 2 scored buys are up 5% or more since purchase, averaging -48%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc | Sold (not open market) | $1.9M |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc | Sold (not open market) | $504K |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc | Sold (not open market) | $174K |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc | Sold (not open market) | $1.1M |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc | Sold (not open market) | $504K |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc | Sold (not open market) | $545K |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc | Sold (not open market) | $478K |
| Jun 18, 2026 | CRNX Crinetics Pharmaceuticals, Inc | Bought (not open market) | — |
| Jun 18, 2026 | CRNX Crinetics Pharmaceuticals, Inc | Bought (not open market) | — |
| Jun 9, 2026 | ATRA Atara Biotherapeutics, Inc | Bought (not open market) | — |
| May 27, 2026 | NMRA Neumora Therapeutics, Inc | Bought (not open market) | — |
| May 14, 2026 | RARE Ultragenyx Pharmaceutical Inc | Bought (not open market) | — |
| May 14, 2026 | RARE Ultragenyx Pharmaceutical Inc | Bought (not open market) | — |
Companies traded
- CRNX Crinetics Pharmaceuticals, Inc: 10 sales, last Sep 1, 2026
- ATRA Atara Biotherapeutics, Inc: 2 sales, last Jun 9, 2026
- NMRA Neumora Therapeutics, Inc: 2 sales, last May 27, 2026
- RARE Ultragenyx Pharmaceutical Inc: 1 buy, 8 sales, last May 14, 2026
- DERM Dermira, Inc: 1 buy, 4 sales, last Feb 20, 2020
- MGNX Macrogenics Inc: other filings, last May 16, 2019
- ONXX Onyx Pharmaceuticals Inc: 22 sales, last Oct 1, 2013